Review
doi: 10.1111/j.1527-3458.2007.00024.x.The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268
Affiliations
- PMID:18078428
- PMCID: PMC6494167
- DOI: 10.1111/j.1527-3458.2007.00024.x
Item in Clipboard
Review
The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268
Gabor Imre. CNS Drug Rev.2007 Winter.
Display options
Format
Display options
Format
Abstract
Activation of group II metabotropic glutamate (mGlu2/3) receptors reduces excessive glutamate release that is often associated with neurodegenerative and psychiatric disorders. This finding encouraged the search for potent and selective agonists as potential therapeutic agents. The search led to the discovery of LY379268 {(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylic acid}, which is a highly potent and systemically available mGlu2/3 receptor agonist. LY379268 was effective in several animal models of stroke, epilepsy, drug abuse, schizophrenia, and pain. Suppression of motor activity is the major side effect of LY379268. Upon repeated administration tolerance develops to this side effect, while the therapeutic effects of LY379268 remain. To date, no clinical data with LY379268 are available. This review article summarizes the preclinical pharmacology of LY379268.
Similar articles
- Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL Jr, Wright RA, Johnson BG, Andis SL, Kingston A, Tomlinson R, Lewis R, Griffey KR, Tizzano JP, Schoepp DD.Monn JA, et al.J Med Chem. 1999 Mar 25;42(6):1027-40. doi: 10.1021/jm980616n.J Med Chem. 1999.PMID:10090786
- The metabotropic glutamate 2/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats.Pitsikas N, Markou A.Pitsikas N, et al.Neuropharmacology. 2014 Oct;85:27-35. doi: 10.1016/j.neuropharm.2014.05.008. Epub 2014 May 20.Neuropharmacology. 2014.PMID:24859609Free PMC article.
- The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.Cartmell J, Monn JA, Schoepp DD.Cartmell J, et al.J Pharmacol Exp Ther. 1999 Oct;291(1):161-70.J Pharmacol Exp Ther. 1999.PMID:10490900
- Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators.Sheffler DJ, Pinkerton AB, Dahl R, Markou A, Cosford ND.Sheffler DJ, et al.ACS Chem Neurosci. 2011 Aug 17;2(8):382-93. doi: 10.1021/cn200008d. Epub 2011 Apr 12.ACS Chem Neurosci. 2011.PMID:22860167Free PMC article.Review.
- Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?DD DD, Marek GJ.DD DD, et al.Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):215-25. doi: 10.2174/1568007024606177.Curr Drug Targets CNS Neurol Disord. 2002.PMID:12769628Review.
Cited by
- Group II metabotropic glutamate receptors modify N-methyl-D-aspartate receptors via Src kinase.Trepanier C, Lei G, Xie YF, MacDonald JF.Trepanier C, et al.Sci Rep. 2013;3:926. doi: 10.1038/srep00926. Epub 2013 Jan 30.Sci Rep. 2013.PMID:23378895Free PMC article.
- mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.Engel M, Snikeris P, Matosin N, Newell KA, Huang XF, Frank E.Engel M, et al.Psychopharmacology (Berl). 2016 Apr;233(8):1349-59. doi: 10.1007/s00213-016-4230-0. Epub 2016 Feb 10.Psychopharmacology (Berl). 2016.PMID:26861891
- Group II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons.Wang MJ, Li YC, Snyder MA, Wang H, Li F, Gao WJ.Wang MJ, et al.PLoS One. 2013 Apr 12;8(4):e61787. doi: 10.1371/journal.pone.0061787. Print 2013.PLoS One. 2013.PMID:23593498Free PMC article.
- Metabotropic group II glutamate receptors mediate cue-triggered increases in reward-seeking behaviour.Garceau C, Marsault J, Robinson MJF, Samaha AN.Garceau C, et al.Psychopharmacology (Berl). 2023 Mar;240(3):515-529. doi: 10.1007/s00213-022-06101-z. Epub 2022 Mar 1.Psychopharmacology (Berl). 2023.PMID:35230468
- Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.Sacchetti E, Turrina C, Valsecchi P.Sacchetti E, et al.Drug Saf. 2010 Apr 1;33(4):273-88. doi: 10.2165/11319120-000000000-00000.Drug Saf. 2010.PMID:20297860Review.
References
- Aghajanian GK, Marek GJ (1999) Serotonin, via 5‐HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825:161‐171. - PubMed
- Anwyl R (1999) Metabotropic glutamate receptors: Electrophysiological properties and role in plasticity. Brain Res Rev 29:83‐120. - PubMed
- Bäckström P, Hyytiä P (2005) Suppression of alcohol self‐administration and cue‐induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)‐3,4‐DCPG. Eur J Pharmacol 528:110‐118. - PubMed
- Barton ME, Peters SC, Shannon HE (2003) Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res 56:17‐26. - PubMed
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources